A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 4,55 (+373,96%). A mediana é € 4,55 (+373,96%).

Comprar
  9
Manter
  5
Vender
  0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Codexis unveils enzymatic ECO‑Synthesis for siRNA and targets kilogram‑scale production by 2027

    At the Cantor Fitzgerald conference, Codexis presented its ECO‑Synthesis platform for enzymatic siRNA manufacture as a capital‑ and solvent‑sparing alternative to solid‑phase organosynthesis, citing roughly 70% higher capital efficiency. Its innovation lab routinely produces 100 grams, plans 500 grams by late 2024/early 2025, and aims for kilogram‑scale production by the end of 2027. The company highlighted technical advances such as stereochemical control and initiation from a single nucleotide, and said it is in ongoing dialogue with the FDA on product specifications and comparability. Codexis is targeting CDMO partnerships, collaborations with pharmaceutical companies and licensing to address siRNA industry scaling bottlenecks. » Mais em de.investing.com


  • Codexis beats Q1 2026 forecasts — revenue more than doubles

    Codexis reported Q1 2026 EPS of -0.10 (expectation -0.16) and revenue of $15.2 million versus $14.79 million expected. Revenue rose 102.7% year over year, mainly due to a technology transfer agreement with Merck; product gross margin improved to 71%. Operating expenses were reduced, net loss narrowed significantly, and cash reserves are expected to fund the business through the end of 2027. For Q2 the company expects around $16.5 million in revenue; the stock rose about 1.5% in after-hours trading. » Mais em de.investing.com


  • Codexis beats Q4 2025 expectations thanks to Merck deal and strong revenue growth

    Codexis reported Q4 2025 EPS of 0.11 USD (expectation -0.04 USD) and revenue of 38.92 million USD, up 81% year-on-year. A technology transfer agreement with Merck contributed 37.8 million USD to quarterly revenue and raised the gross margin to 64%. For the full year the company still records a net loss of 44 million USD despite the quarter’s results, expects negative EPS for 2026, and is focused on expanding the ECO-Synthesis platform and a GMP production facility by the end of 2027. » Mais em de.investing.com


  • Codexis signs manufacturing deal for 50 g siRNA to support preclinical development

    Codexis agreed with a pharmaceutical company to manufacture 50 grams of siRNA using its ECO Synthesis platform to support a preclinical candidate for a cardiovascular indication. The order is intended to demonstrate that the platform can deliver quantities beyond early research volumes and lays the groundwork for potential scale‑up if the program advances. Financial terms and the partner’s name were not disclosed; the stock trades near its 52‑week low, but analysts have recently raised estimates and price targets. » Mais em de.investing.com


  • Codexis aligns strategy toward RNA therapeutics and plans GMP production

    Codexis announced at the TD Cowen Healthcare Conference a strategic realignment toward RNA therapeutics, leveraging its ECO synthesis platform to scale and improve efficiency. A new GMP production facility, with investments of $20–25 million, is planned to be operational by 2027; scaling production to kilogram levels is planned by the end of 2026. The company sees an addressable market of about $2 billion for RNA medicines by 2030, has 11 drug candidates in Phase 3, and has signed a supply agreement with Merck to strengthen its supply chain. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Codexis registou receitas de € 17,01 mi e um ganho líquido de -€ 7,18 mi
(EUR) setembro de 2026
YoY
Receitas 17,01 mi 132,02%
Ganho bruto 13,46 mi 157,46%
Ganho líquido -7,18 mi 57,07%
EBITDA -4,98 mi 63,96%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 106,8 mi
Número de ações
109,6 mi
Máximo/mínimo de 52 semanas
€ 2,71 - € 0,82
Dividendos Não
Beta
2,39
PER (PE Ratio)
-5,46
PEG (PEG Ratio)
-0,03
P/VC (PB Ratio)
2,24
P/V (PS Ratio)
1,33

Perfil da empresa

A Codexis, Inc. descobre, desenvolve e vende enzimas e outras proteínas. Oferece produtos e serviços de biocatalisadores; produtos de químicos intermédios, utilizados para processamento químico adicional; e painéis e kits de biocatalisadores Codex, que permitem aos clientes realizar rastreio de química. A empresa também presta serviços de rastreio de biocatalisadores e de engenharia de proteínas. Além disso, disponibiliza a plataforma tecnológica de engenharia de proteínas CodeEvolver, que ajuda a desenvolver e fornecer biocatalisadores que realizam transformações químicas e melhoram a eficiência e a produtividade dos processos de fabrico. A plataforma da empresa é também utilizada para descobrir novos candidatos a fármacos bioterapêuticos para doenças humanas específicas, bem como para biologia molecular e enzimas de diagnóstico in vitro. A empresa vende os seus produtos a fabricantes farmacêuticos através da sua força de vendas direta e de desenvolvimento de negócio nos Estados Unidos e na Europa. A empresa foi constituída em 2002 e tem a sede em Redwood City, Califórnia.

Nome
Codexis
CEO
Alison Moore
Sede Redwood City, ca
EUA
Site
Setor
Energia
Indústria
Petróleo, gás e combustíveis não renováveis
Entrada em bolsa
22/04/2010
Colaboradores 146

Símbolos de ticker

Bolsa Símbolo
NASDAQ
CDXS
London Stock Exchange
0I0X.L
Frankfurt
4QK.F
Düsseldorf
4QK.DU
London
0I0X.L
SIX
4QK.SW
München
4QK.MU
🍪

Parqet  utiliza cookies. Saber mais